Investing.com - Financial Markets Worldwide
🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Pain Therapeutics (PTIE) Down On CRL For Chronic Pain Drug

ByZacks Investment Research
Published 09/27/2016, 10:52 PM
Updated 07/09/2023, 06:31 AM
ABT
-
ANIK
-
SAVA
-
ANIP
-
Pain Therapeutics Inc.’s (NASDAQ:PTIE) shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). The company was looking to get Remoxy approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are inadequate. Overall, the company’s shares have declined 56.4%.
The FDA said that Remoxy cannot be approved in its present form. In the CRL, the agency has asked the company to conduct additional studies that are required to gain approval for Remoxy, with label claims on three routes of abuse (injection, inhalation and snorting).
The company had also sought for a label claim against abuse by chewing. In its CRL, the FDA asked company to submit a revised label proposal for the claim.
However, the company confirmed that the FDA did not bring up any safety, efficacy, manufacturing, stability, bioequivalence or any other issue that were raised in the previous CRL. We remind investors that this is the third time that the FDA has issued a CRL for Remoxy.
Pain Therapeutics said that it is currently evaluating the CRL and intends to hold further discussions with the regulatory body. The company said that the additional actions requisitioned by the FDA in the CRL may take approximately a year to conduct and cost the company about $5 million.

The CRL is a huge setback for the company as it is highly dependent on Remoxy for growth and has no approved product in its portfolio. A positive response from the agency would have enabled the company to launch its first drug.

PAIN THERAPEUT Price

PAIN THERAPEUT Price | PAIN THERAPEUT Quote

Zacks Rank & Key Picks

Pain Therapeutics currently carries a Zacks Rank #2 (Buy). Some other favorably placed stocks in health care sector include Anika Therapeutics Inc (NASDAQ:ANIK) , ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Abbott Laboratories (NYSE:ABT) . All the three stocks sport a a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 22% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 54.8% year to date.
Corcept Therapeutics’ earnings estimates for 2016 and 2017 were up 25% and 12.5%, respectively, over the past 60 days. Share price of the company have soared 40.5% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



ABBOTT LABS (ABT): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

PAIN THERAPEUT (PTIE): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.